Showing results (51-60 of 214) with videos related to

Sort By:
Pageof 22
AIDS (London, England)|November 13, 2015
Mechanisms of bone disease in HIV and hepatitis C virus: impact of bone turnover, tenofovir exposure, sex steroids and severity of liver diseaseRoger Bedimo, James Cutrell, Song Zhang, et al.
Plos One|November 9, 2020
Investigating hospital Mycobacterium chelonae infection using whole genome sequencing and hybrid assemblyChristopher H Gu, Chunyu Zhao, Casey Hofstaedter, et al.
The Journal of Clinical Investigation|July 16, 2004
The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signalingMichael W-H Wang, Shi Wei, Roberta Faccio, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 15, 2014
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trialsPablo Tebas, Michael Sension, José Arribas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 15, 2005
Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infectionKristin Mondy, William G Powderly, Sherry A Claxton, et al.
AIDS (London, England)|August 2, 2008
Genetic analysis implicates resistin in HIV lipodystrophyKoustubh Ranade, William J Geese, Mustafa Noor, et al.
HIV Clinical Trials|February 27, 2016
Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trialEdgar Turner Overton, Pablo Tebas, Bruce Coate, et al.
AIDS (London, England)|September 28, 2010
European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142Todd Hulgan, Richard Haubrich, Sharon A Riddler, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
BACH2-driven tissue resident memory programs promote HIV-1 persistenceYulong Wei, Haocong Katherine Ma, Michelle E Wong, et al.
Pathogens & Immunity|January 2, 2020
Evidence for Persistent Monocyte and Immune Dysregulation After Prolonged Viral Suppression Despite Normalization of Monocyte Subsets, sCD14 and sCD163 in HIV-Infected IndividualsAnjana Yadav, Andrew V Kossenkov, Vincent R Knecht, et al.
Pageof 22